Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARTER: First Lines of Biologics in Patients With Ulcerative Colitis
NCT07576452Phase 4Not yet recruiting
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Dec 2026
- Primary completion
- Jun 2030
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 4 trial of infliximab, filgotinib, ustekinumab, vedolizumab in ulcerative colitis (UC), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
infliximabfilgotinibustekinumabvedolizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07576452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07576452.